content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                         -----------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 17, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ------------------------------   ------------------------    -------------------
   (State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
         of Incorporation)                                     Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  ----------------------------------------------------------      ----------------
          (Address of Principal Executive Offices)                   (Zip Code)
  
  
         Registrant's telephone number, including area code: (609) 750-8200
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange  Act  (17  CFR  240.13e-4(c))
  
  
  <PAGE>
  
  
  ITEM 5.03  AMENDMENTS TO ARTICLES OF  INCORPORATION OR BY-LAWS; CHANGE IN FISCAL
             YEAR.
  
       On October  17,  2006,  the Board of  Directors  (the  "Board")  of Cytogen
  Corporation (the "Company") resolved to immediately amend Article III, Section 6
  of the  Company's  By-Laws to  decrease  the number of days  notice that must be
  given to call a special  meeting of the Board from two days' notice to one days'
  notice.  The  Company's  Amended and  Restated  By-Laws are  attached  hereto as
  Exhibit 3.1 and incorporated herein by reference.  The foregoing  description of
  the Amended and  Restated  By-Laws is  qualified in its entirety by reference to
  such Exhibit.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
  
  (c)  Exhibits.
  
        Exhibit No.       Description
        -----------       -----------
  
           3.1            Amended and Restated By-Laws of Cytogen Corporation
  
  
  
  
  <PAGE>
  
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
  
  
                                          By:  /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated: October 19, 2006
  
  
  
  
  <PAGE>
  
  
                                    EXHIBIT INDEX
  
  
        Exhibit No.       Description
        -----------       -----------
  
            3.1           Amended and Restated By-Laws of Cytogen Corporation
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_bylaws-amend101906.txt", "description": "FORM 8-K RE BYLAWS AMENDMENT", "secsgml_size_bytes": 3930}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "061153804"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                         -----------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
         Date of report (Date of earliest event reported): October 17, 2006
                                                           ----------------
  
                                 CYTOGEN CORPORATION
                 --------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
             Delaware                     000-14879                 22-2322400
  ------------------------------   ------------------------    -------------------
   (State or Other Jurisdiction    (Commission File Number)     (I.R.S. Employer
         of Incorporation)                                     Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ            08540
  ----------------------------------------------------------      ----------------
          (Address of Principal Executive Offices)                   (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange  Act  (17  CFR  240.13e-4(c))
  ITEM 5.03  AMENDMENTS TO ARTICLES OF  INCORPORATION OR BY-LAWS; CHANGE IN FISCAL
             YEAR.
  
       On October  17,  2006,  the Board of  Directors  (the  "Board")  of Cytogen
  Corporation (the "Company") resolved to immediately amend Article III, Section 6
  of the  Company's  By-Laws to  decrease  the number of days  notice that must be
  given to call a special  meeting of the Board from two days' notice to one days'
  notice.  The  Company's  Amended and  Restated  By-Laws are  attached  hereto as
  Exhibit 3.1 and incorporated herein by reference.  The foregoing  description of
  the Amended and  Restated  By-Laws is  qualified in its entirety by reference to
  such Exhibit.
  
  ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS
  
  (c)  Exhibits.
  
        Exhibit No.       Description
        -----------       -----------
  
           3.1            Amended and Restated By-Laws of Cytogen Corporation
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                          CYTOGEN CORPORATION
  
                                          By:  /s/ Michael D. Becker
                                             -------------------------------------
                                             Michael D. Becker
                                             President and Chief Executive Officer
  
  Dated: October 19, 2006
  EXHIBIT INDEX
  
        Exhibit No.       Description
        -----------       -----------
  
            3.1           Amended and Restated By-Laws of Cytogen Corporation